MYMX 财务： Mymetics Corp AI 分析

主页

股票

MYMX

财务数据

MYMX 财务

Mymetics Corp

收盘价：Apr 02, 16:00:00 GMT-4

盘后：Apr 02, 20:00:00 GMT-4

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

MYMX 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
营收	0	1	0	0	0	0
营收同比增长 (YoY)	--	--	--	--	--	-100%
营收成本	--	--	--	--	--	--
毛利润	--	--	--	--	--	--
销售、一般及管理费用	1	1	1	1	1	1
研发	1	1	0	1	0	1
营业费用	2	2	2	2	2	2
其他非经营性收入 (费用)	0	0	0	0	--	--
税前利润	-11	-4	-4	-4	-4	-4
所得税费用	--	0	0	0	0	0
净利润	-11	-4	-4	-4	-4	-4
净利润增长	120%	0%	0%	0%	0%	0%
稀释后流通股数	0.15	0.15	0.15	0.15	303.75	303.75
股份同比变动 (YoY)	-100%	0%	0%	-100%	0%	0%
每股收益 (摊薄)	-76.15	-31.63	-31.14	-27.37	-0.01	-0.01
每股收益增长率	450,492%	2%	14%	198,285%	1%	1%
自由现金流	-1	-1	-1	-1	-1	-2
每股自由现金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
营业利润率	0%	-100%	0%	0%	0%	0%
净利率	0%	-400%	0%	0%	0%	0%
自由现金流利润率	0%	-100%	0%	0%	0%	0%
EBITDA	-2	-1	-1	-1	-1	-1
EBITDA 利润率	0%	-100%	0%	0%	0%	0%
EBITDA 中的折旧与摊销	0	0	0	0	0	0
EBIT	-2	-1	-1	-1	-1	-1
EBIT 利润率	0%	-100%	0%	0%	0%	0%
有效税率	--	0%	0%	0%	0%	0%

Follow-Up Questions

Mymetics Corp 的关键财务报表是什么？



根据最新的财务报表（Form-10K），Mymetics Corp 的总资产为 $7，净损失为 $-4

MYMX 的关键财务比率是什么？



Mymetics Corp 的流动比率是 0.09，净利 margin 为 -400，每股销售为 $6.58。

Mymetics Corp 的收入按细分市场或地理位置如何划分？



Mymetics Corp 最大收入来源是 Automotive，在最近的收益报告中收入为 538,894,000,000。就地区而言， United States 是 Mymetics Corp 的主要市场，收入为 165,243,000,000。

Mymetics Corp 是否盈利？



不，根据最新的财务报表，Mymetics Corp 的净损失为 $-4

Mymetics Corp 有负债吗？



是的，Mymetics Corp 的负债为 72

Mymetics Corp 的流通股有多少？



Mymetics Corp 的总流通股为 0.15

关键数据

前收盘价

$0.0003

开盘价

$0.0003

当日区间

$0.0003 - $0.0003

52周范围

$0.0003 - $0.0003

交易量

100

平均成交量

股息收益率

每股收益（TTM）

-70.19

市值

$44.99999999999999

什么是 MYMX？

Mymetics Corp. is a vaccine company, which focuses on the research and development of next generation vaccines for infectious and life disabling diseases. The company is headquartered in Epalinges, Vaud and currently employs 8 full-time employees. The firm is focused on developing vaccines for infectious diseases. The firm has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

功能特性

资源